Beta-bloqueantes e outros fármacos redutores do cronotropismo cardíaco
235235
Bibliografia
1. “Sir James W. Black ‑ Facts”. Nobelprize.org. Nobel Media AB 2014.Web. 4 Nov2015. http://
2. MeulenVD. Beta‑blockers: ancillary properties important after all? Eastern Journal of Medicine.
1999; 4: 1‑5.
3. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in
patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med.
1996;334:1349‑55.
4. Koch‑Weser J, Frishman WH. Beta‑adrenoceptor antagonists: New drugs and new indications.
N Engl J Med. 1981; 305:500‑6
5. Mukherjee D, Fang J, Chetcuti S et al. impact of combination evidence‑based medical therapy on
mortality in patients with acute coronary syndromes. Circulation. 2004;109:745‑749.
6. Yusuf S,Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease.
I.Treatments following myocardial infarction. JAMA. 1988;260: 2088–2093.
7. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial
infarction treated with acute beta‑blocker therapy: results from the American College of
Cardiology’s NCDRw. Am Heart J. 2011;161:864–870.
8. Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial
infarction in patients presenting with ST‑segment elevation. Eur Heart J. 2012, 33:2569‑2619
9. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease
progression in heart failure. J Am Coll Cardiol. 1992; 20:248‑254.
10. Brophy JM, Joseph L, Rouleau JL. Beta‑blockers in congestive heart failure. A Bayesian
meta‑analysis.Ann Intern Med. 2001; 134:550‑560.
11. Foody JM, Farrell MH, Krumholz HM. beta‑Blocker therapy in heart failure: scientific review.
JAMA. 2002; 287:883.
12. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with
severe chronic heart failure: results of the carvedilol prospective randomized cumulative
survival (COPERNICUS) study. Circulation. 2002; 106:2194.
13. Goldstein S, Fagerberg B, Kjekshus J, et al. Metoprolol controlled release/extended release in
patients with severe heart failure: analysis of the experience in the MERIT‑HF study. J Am Coll
Cardiol. 2001; 38:932.
14. European Heart RhythmAssociation, EuropeanAssociation for Cardio‑Thoracic Surgery, Camm
AJ, et al. Guidelines for the management of atrial fibrillation: theTask Force for the Management
of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31:2369.
15. Law MR, Morris JK,Wald NJ. Use of blood pressure lowering drugs in the prevention of
cardiovascular disease: meta‑analysis of 147 randomised trials in the context of expectations
from prospective epidemiological studies. BMJ. 2009;338:b1665.
16. Swedberg K, Komajda M, Bohm M, et. al. Ivabradine and outcomes in chronic heart failure
(SHIFT): a randomised placebo‑controlled study. Lancet. 2010;376:875–885.
17. Fox K, Ford I, Steg PG, et al, for the SIGNIFY Investigators. Ivabradine in Stable CoronaryArtery
Disease without Clinical Heart Failure N Engl J Med. 2014; 371:1091‑1099
